ISOPTIN

This brand name is authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, Germany, Hong Kong SAR China, Ireland, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Turkey.

Active ingredients

The drug ISOPTIN contains one active pharmaceutical ingredient (API):

1	Verapamil UNII V3888OEY5R - VERAPAMIL HYDROCHLORIDE
	Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease.
	Read more about Verapamil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ISOPTIN Film‐coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)
ISOPTIN Solution for injection / infusion	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C08DA01	Verapamil	C Cardiovascular system → C08 Calcium channel blockers → C08D Selective calcium channel blockers with direct cardiac effects → C08DA Phenylalkylamine derivatives
Discover more medicines within C08DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1241H, 1250T, 2208F
CA	Health Products and Food Branch	00742554, 01907123, 01934317
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00530896, 01284330, 01976772, 02459323, 02709406, 02709458, 02709464, 02791342, 03573825, 03573831
EE	Ravimiamet	1017267, 1017278, 1073157, 1073180
FI	Lääkealan turvallisuus- ja kehittämiskeskus	508622, 559021
HK	Department of Health Drug Office	01261, 26481
HR	Agencija za lijekove i medicinske proizvode	HR-H-043595484, HR-H-343032655, HR-H-487117669, HR-H-998142642
IE	Health Products Regulatory Authority	29424, 29521, 29548, 38933, 39470
IT	Agenzia del Farmaco	020609044, 020609069, 020609083
LT	Valstybinė vaistų kontrolės tarnyba	1002853, 1002855, 1090534
MT	Medicines Authority	AA1187/01601, AA1187/01602, AA565/78701
NL	Z-Index G-Standaard, PRK	26832, 34800, 35408
NZ	Medicines and Medical Devices Safety Authority	1665, 1666, 1667, 1669, 1670
PL	Rejestru Produktów Leczniczych	100010337, 100030363, 100031434, 100032391, 100426411, 100446632, 100449056, 100458000, 100463200
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68848001
SG	Health Sciences Authority	00344P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699548030420, 8699548031953, 8699548090806, 8699548090820, 8699548750793, 8699548755255, 8699548755262
ZA	Health Products Regulatory Authority	D/7.1.4/118, R/7.1.4/195, V/7.1/280